Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients

Development of a Peripheral Blood Assay to Replace Bone Marrow Biopsy in Myeloproliferative Neoplasms- a Multi-center Observational Study

This observational, multi-center study aims to collect data to develop a novel, minimally invasive diagnostic tool for myeloproliferative neoplasms (MPN) based on peripheral blood (PB) profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing (scRNA-seq). Current diagnostic practice relies on bone marrow (BM) biopsy, procedures that is invasive, technically demanding, and may be inconclusive in early or prefibrotic disease stages.

Our prior work established a reference atlas of healthy cHSPC subtypes and a computational pipeline capable of identifying disease-specific transcriptional changes by quantifying deviations from this reference. This study will assess whether PB-based genomic profiling can accurately distinguish MPN from non-clonal cytoses, including secondary erythrocytosis or thrombocytosis.

Patients referred for bone marrow biopsy due to suspected myeloproliferative neoplasm (MPN) will undergo PB collection for genomic profiling. The study's primary objective is to develop a PB-based test by comparing the developed test diagnoses to the conventional BM-based diagnostics. Secondary objectives include evaluating its potential for MPN subtype classification, risk stratification, as well as assessing its ability to reduce the need for BM biopsies.

Study Overview

• Status: Not yet recruiting
• Conditions: Myeloproliferative Neoplasm
• Intervention / Treatment: Diagnostic test: PERIBLOOD-MPN

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Liran Shlush, Prof.; Phone Number: +97289342247; Email: liran.shlush@weizmann.ac.il
• Study Contact Backup: Name: Gil Gonen Yaacovi, PhD; Phone Number: +9728747027401; Email: gil.gonen-yaacovi@weizmann.ac.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

Patients with MPN, or suspicion for MPN, who are referred to BM will be recruited to the study

Description

Inclusion Criteria:

1. Age ≥ 18 years

2. Confirmed MPN diagnosis, based on the WHO criteria (Barbui 2018), which includes:

   Polycythemia Vera (PV) Criteria:

   • Elevated hemoglobin (>16.5 g/dL for men, >16.0 g/dL for women), hematocrit (>49% for men, >48% for women), or increased red cell mass
   • Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis)
   • Presence of JAK2 mutation (V617F or exon 12)

   Essential Thrombocythemia (ET) Criteria:

   • Platelet count ≥450 ×10⁹/L
   • Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage
   • Not meeting WHO criteria (Alaggio et al., 2022) for other myeloid neoplasms (such as CML, PV, PMF, MDS).
   • Presence of JAK2, CALR, or MPL mutation Primary Myelofibrosis (PMF) Criteria
   • Megakaryocytic proliferation and atypia, with or without reticulin fibrosis, and increased marrow cellularity (for prefibrotic/early PMF) or significant reticulin/collagen fibrosis (for overt PMF)
   • Not meeting criteria for other myeloid neoplasms
   • Presence of JAK2, CALR, or MPL mutation, or in their absence, another clonal marker
3. Patients who are referred for a bone marrow biopsy due to a suspected diagnosis of MPN

Exclusion Criteria:

1. Patients diagnosed with MPN receiving therapy
2. Patients who have undergone a bone marrow transplant

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To development PERIBLOOD-MPN Diagnostic Test	Development of PERIBLOOD-MPN Diagnostic Test Using PB-Derived CD34+ cHSPCs for Diagnosis of MPN	Three months following the PB sample

Collaborators and Investigators

• Sponsor: Weizmann Institute of Science

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): June 1, 2032

Study Registration Dates

• First Submitted: June 9, 2026
• First Submitted That Met QC Criteria: June 9, 2026
• First Posted (Actual): June 15, 2026

Study Record Updates

• Last Update Posted (Actual): June 15, 2026
• Last Update Submitted That Met QC Criteria: June 9, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Bone Marrow Diseases; Hemic and Lymphatic Diseases; Myeloproliferative Disorders
• Other Study ID Numbers: PERIBLOOD-MPN

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: We will send PERIBLOOD report including the genetic data, for each patients, to the participating sites

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes